Work

POSTER: MM-1119: Arlocabtagene Autoleucel in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma: Final Analysis From the Phase 1 Study

Year: 2026

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(26)01413-8

Authors: Susan Bal, Myo Htut, Omar Nadeem, Larry Anderson, Tara Gregory, Mehmet Koçoglu, Adriana Rossi, Luciano Costa, Hongxiang Hu, Ziyan Guo, Noah Kaitz, Naomey Sarkis, Safiyyah Ziyad, Kristina Jordahl, Wei-Ming Kao, Allison Kaeding, Michael Burgess, Jesus Berdeja

Institutions: University of Alabama at Birmingham, City Of Hope National Medical Center, Dana-Farber Cancer Institute, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Colorado Blood Cancer Institute, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Icahn School of Medicine at Mount Sinai, Bristol-Myers Squibb (United States), Tennessee Oncology

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7204686703

FWCI:

Cites:

Cited by:

Related to: